Close Menu

NEW YORK – Proteomics firm Seer said on Wednesday that it has priced an underwritten public offering of 3.75 million shares of Class A common stock at $67 per share.

The offering will consist of 1.65 million shares sold by Seer and 2.1 million shares sold by stockholders of Seer. Gross proceeds to Seer will be around $110.5 million.

Additionally, the selling stockholders will grant the underwriters a 30-day option to purchase up to 562,500 additional shares of Class A common stock at the public offering price, less underwriting discounts and commissions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.